Year: 2025

Tucson Water Enters New Era of Innovation with Cellular-Based AMI LIBERTY LAKE, Wash., Dec. 09, 2025 (GLOBE NEWSWIRE) — Itron, Inc. (NASDAQ: ITRI), which is innovating new ways for utilities and cities to manage energy and water, is working with the City of Tucson | Tucson Water in Arizona to enhance water conservation efforts with Itron’s Advanced Metering Infrastructure (AMI) Essentials for water. AMI Essentials for water is Itron’s new standard bundled AMI solution, tailored to better serve small- to medium-sized water utilities in the United States. In geographical areas where water preservation is at the forefront of sound water resource management, effective conservation requires greater visibility into the water distribution network. This deployment marks a new era of innovation for the city as it lays the technological...

Data highlights the ability of Akari’s Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest survival rates  The K-Ras G12V mutation is the oncogenic driver for 1/3 of all pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer Significant unmet need in pancreatic cancer where median overall survival (OS) is 1.4 years1 TAMPA, Fla. and LONDON, Dec. 09, 2025 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced key preclinical data demonstrating the therapeutic potential of its novel ADC targeting Trop2, AKTX-101, in pancreatic cancer driven by K-Ras mutations, one of the deadliest and most...

Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad patient population1 Olanzapine LAI is designed to help support real-world adherence and improved stability, with the goal of addressing a critical treatment gap for people living with schizophrenia1 Teva is committed to advancing this innovative treatment option and further build on its differentiated LAI franchisePARSIPPANY, N.J. and TEL AVIV, Israel, Dec. 09, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for olanzapine extended-release injectable suspension (TEV-‘749) for the treatment...

New solution suite and site enhance sports advertising – across screens and seasons – with data, creative and premium supply NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) — Nexxen, a global, flexible advertising technology platform with deep expertise in data and advanced TV, today announced the launch of Nexxen Sports, a new suite of solutions that combines premium, live sports content with data-driven audience insights, targeting and dynamic creative to connect brands with highly engaged sports fans across devices. According to Nexxen’s Inside Live Sports research, 48% of Americans watch live sports, with 85% of them tuning in weekly or more. Built on Nexxen’s unified, data-led platform, including a demand-side platform (“DSP”) and supply-side platform (“SSP”), Nexxen Sports enables advertisers to reach and engage these viewers...

PHILADELPHIA, Dec. 09, 2025 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced the appointments of Han Lee, Ph.D., M.B.A., and Martin Murphy, Ph.D., to its Board of Directors. As part of their appointments, Dr. Lee will serve as a member of the Audit and the Compensation Committees and Dr. Murphy will serve as a member of the Compensation and the Nominating and Corporate Governance Committees. “We are pleased to welcome Dr. Lee and Dr. Murphy to our Board at an important time for Century as we execute with discipline and focus to bring our most differentiated iPSC-derived cell therapy programs, including CNTY-813 as a potentially curative, off-the-shelf investigational...

Company Finalizes GlycoCheck® License, Advances DocSun AI Acquisition and SDK Partnerships, and Engages Investment Bank for Planned 2026 Initiatives CHATTANOOGA, Tenn., Dec. 09, 2025 (GLOBE NEWSWIRE) — BioRegenx, Inc. (“BioRegenx” or the “Company”) (OTC: BRGX), a health-technology company pioneering non-invasive diagnostic and predictive analytics solutions for microvascular and metabolic health, today announced a series of significant corporate, technological, and strategic milestones. HighlightsEngaged a new PCAOB-registered independent auditor following industry-wide SEC actions affecting prior firms. Finalized intellectual property license for the clinically validated GlycoCheck® vascular diagnostic platform. Fully integrated DocSun Biomedical Holdings, Inc., adding AI-driven non-contact vital-sign detection and SDK licensing...

VANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) —  HydroGraph Clean Power Inc. (CSE: HG) (OTCQB: HGRAF) (“HydroGraph” or the “Company”) today announced that James Baker will join the Company’s Technical Advisory Board (TAB), bringing more than three decades of experience in advanced materials, aerospace, defence, and graphene commercialisation. For the last 12 years, Mr. Baker led business activities related to graphene and 2D materials at the University of Manchester, including serving as Chief Executive Officer of the globally recognized Graphene Engineering Innovation Centre (GEIC). Prior to his work in graphene, he spent 25 years in the aerospace and defence industry in senior roles focused on technology development and industrial innovation at BAE Systems and Pilkington Optronics. Mr. Baker has announced that he...

All figures are in US dollars unless otherwise stated. LEWISVILLE, Ark., Dec. 09, 2025 (GLOBE NEWSWIRE) — Smackover Lithium, a Joint Venture (“JV”) between Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE.A: SLI) and Equinor, is providing an update with respect to the project financing being pursued for the South West Arkansas Project (“SWA Project” or the “Project”). Smackover Lithium has received expressions of interest from three major Export Credit Agencies (“ECAs”), including among them Export-Import Bank of the United States (EXIM) and Export Finance Norway (Eksfin), for over $1 billion in senior secured project debt (the “ECA Financing”) to fund the construction of Phase 1 of the SWA Project.   Smackover Lithium is currently seeking a senior secured, limited recourse debt financing package of...